{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:01:25Z","timestamp":1776690085888,"version":"3.51.2"},"reference-count":42,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This work was supported by the Italian Ministry of Health Grant.","award":["GR-2021-12375403"],"award-info":[{"award-number":["GR-2021-12375403"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,22]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>To evaluate the trend of prescription of the four foundational therapies, and their impact on 30-day urgent re-admissions and all-cause death in patients with heart failure and reduced ejection fraction (HFrEF) following an acute decompensation event.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design<\/jats:title>\n<jats:p>Retrospective.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Setting<\/jats:title>\n<jats:p>One tertiary referral centre.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Participants<\/jats:title>\n<jats:p>999 consecutively patients admitted with a primary diagnosis of HFrEF between January 2020 and June 2023 were identified through a validated, high\u2010performance technology infrastructure based on artificial intelligence. The entire cohort was divided into three time periods based on two time points: September 2021 (ie, the release of the latest European guidelines) and January 2022 (ie, reimbursement for sodium-glucose cotransporter 2 (SGLT2) inhibitors).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Primary and secondary outcome measures<\/jats:title>\n<jats:p>Trends and predictors of the prescription of each of the four foundational therapies and of the composite of all-cause death and rehospitalisation for urgent causes at 30 days.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among the 999 included patients, \u03b2-blockers were prescribed in 93% of patients, ACE inhibitor (ACEi)\/angiotensin receptor blocker (ARB)\/angiotensin\u2013neprilysin receptor inhibitor (ARNi) in 73%, mineralocorticoid receptor antagonist in 30% and SGLT2 inhibitors in 18%. Over time, an increase in the prescription rate occurred only for SGLT2 inhibitors (3% vs 10% vs 32%, p&lt;0.001), whereas the rate of the composite of all-cause death and rehospitalisation for urgent causes at 30 days remained stable (9.9% vs 10.3% vs 8.4%; p=ns). In multivariate analysis, the use of ACEi\/ARB\/ARNi was associated with a lower risk of 30-day all-cause death and urgent rehospitalisation (adjusted OR 0.38; 95% CI 0.24 to 0.59; p&lt;0.01). Conversely, the prescription of furosemide at discharge (adjusted OR 2.25; 95% CI 95% 1.29 to 3.94; p&lt;0.01) and a previous genitourinary infection (adjusted OR 4.02; 95% CI 1.67 to 9.68; p&lt;0.01) were associated with higher risk of 30-day all-cause death and urgent rehospitalisation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In our study, early adoption of guideline-recommended medical therapy is still limited, with a significant rise in SGLT2i prescriptions after January 2022 and a lower risk of the composite of all-cause death and urgent readmissions at 30 days restricted to the use of ACEi\/ARB\/ARNi.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088998","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:40:45Z","timestamp":1739014845000},"page":"e088998","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Temporal trends in guideline-recommended medical therapy after an acute heart failure decompensation event: an observational analysis from Generator Heart Failure DataMart"],"prefix":"10.1136","volume":"15","author":[{"given":"Renzo","family":"Laborante","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agni","family":"Delvinioti","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrada Mihaela","family":"Tudor","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, Oncological Radiotherapy and Hematology, Catholic University of the Sacred Heart, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Lenkowicz","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Iacomini","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Iaconelli","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy"},{"name":"University of Glasgow, Glasgow, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato Antonio","family":"Paglianiti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"},{"name":"GVM Care and Research, Cotignola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Rodolico","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Patarnello","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Restivo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ciliberti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Dipartimento di MedicinaTraslazionale, Universit\u00e0 del Piemonte Orientale, Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Busti","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Sensini","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Valentini","sequence":"additional","affiliation":[{"name":"Department of Bioimaging Radiation Oncology and Hematology, Universit\u00e0 Cattolica S, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, IRCCS 'A Gemelli' University Polyclinic Foundation, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Crea","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Cesario","sequence":"additional","affiliation":[{"name":"Gemelli Digital Medicine & Health Srl, Roma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset, S\u00f6dersjukhuset and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[{"name":"Dipartimento di MedicinaTraslazionale, Universit\u00e0 del Piemonte Orientale, Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-8330","authenticated-orcid":false,"given":"Domenico","family":"D'Amario","sequence":"additional","affiliation":[{"name":"Dipartimento di MedicinaTraslazionale, Universit\u00e0 del Piemonte Orientale, Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"2025070104270834000_15.2.e088998.1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013"},{"key":"2025070104270834000_15.2.e088998.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2025070104270834000_15.2.e088998.3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029071","article-title":"Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge","volume":"12","author":"D\u2019Amario","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2025070104270834000_15.2.e088998.4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/ehjcvp\/pvae047","article-title":"Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials","volume":"10","author":"Laborante","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070104270834000_15.2.e088998.5","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2015.14"},{"key":"2025070104270834000_15.2.e088998.6","doi-asserted-by":"crossref","first-page":"1104699","DOI":"10.3389\/fcvm.2023.1104699","article-title":"Generator heart failure DataMart: An integrated framework for heart failure research","volume":"10","author":"D\u2019Amario","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2025070104270834000_15.2.e088998.7","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1093\/eurheartj\/ehac426","article-title":"CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research","volume":"43","author":"Kotecha","year":"2022","journal-title":"Eur Heart J"},{"key":"2025070104270834000_15.2.e088998.8","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.1266"},{"key":"2025070104270834000_15.2.e088998.9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.566"},{"key":"2025070104270834000_15.2.e088998.10","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jcma.2017.04.011","article-title":"Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry","volume":"80","author":"Chang","year":"2017","journal-title":"J Chin Med Assoc"},{"key":"2025070104270834000_15.2.e088998.11","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.cardfail.2022.02.011","article-title":"Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The Victoria Registry","volume":"28","author":"Greene","year":"2022","journal-title":"J Card Fail"},{"key":"2025070104270834000_15.2.e088998.12","first-page":"1320","article-title":"Mortality, Outcomes, Costs, and Use of Medicines Following a First Heart Failure Hospitalization","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC: Heart Failure"},{"key":"2025070104270834000_15.2.e088998.13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/ejhf.2928","article-title":"Association between a hospitalization for heart failure and the initiation\/discontinuation of guideline-recommended treatments: An analysis from the Swedish Heart Failure Registry","volume":"25","author":"Schrage","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025070104270834000_15.2.e088998.14","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025070104270834000_15.2.e088998.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.049"},{"key":"2025070104270834000_15.2.e088998.16","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jchf.2024.03.001","article-title":"Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure","volume":"12","author":"Greene","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2025070104270834000_15.2.e088998.17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000457946","article-title":"Discontinuation\/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction","volume":"137","author":"Kane","year":"2017","journal-title":"Cardiology"},{"key":"2025070104270834000_15.2.e088998.18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025070104270834000_15.2.e088998.19","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020474","article-title":"Sacubitril\/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Na\u00efve With Heart Failure and Reduced Ejection Fraction","volume":"10","author":"Mohanty","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025070104270834000_15.2.e088998.20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025070104270834000_15.2.e088998.21","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025070104270834000_15.2.e088998.22","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"European J of Heart Fail"},{"key":"2025070104270834000_15.2.e088998.23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2971"},{"key":"2025070104270834000_15.2.e088998.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2022.08.009"},{"key":"2025070104270834000_15.2.e088998.25","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ejhf.2483","article-title":"Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata","volume":"24","author":"Stolfo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025070104270834000_15.2.e088998.26","doi-asserted-by":"crossref","first-page":"20543581231217857","DOI":"10.1177\/20543581231217857","article-title":"Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research","volume":"11","author":"Yi","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"2025070104270834000_15.2.e088998.27","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0005722022"},{"key":"2025070104270834000_15.2.e088998.28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ejhf.2103","article-title":"Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades","volume":"23","author":"Kimmoun","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025070104270834000_15.2.e088998.29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l223"},{"key":"2025070104270834000_15.2.e088998.30","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/jamacardio.2022.2213","article-title":"Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019","volume":"7","author":"Jain","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025070104270834000_15.2.e088998.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.04.047"},{"key":"2025070104270834000_15.2.e088998.32","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/imj.14289","article-title":"Discharge treatment with angiotensin\u2010converting enzyme inhibitor\/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction","volume":"49","author":"Vicent","year":"2019","journal-title":"Intern Med J"},{"key":"2025070104270834000_15.2.e088998.33","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00392-020-01598-w","article-title":"Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction","volume":"109","author":"Ter Maaten","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"2025070104270834000_15.2.e088998.34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ejhf.3179","article-title":"Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial","volume":"26","author":"Ezekowitz","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2025070104270834000_15.2.e088998.35","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/ejhf.1796","article-title":"Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry","volume":"22","author":"Kapelios","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2025070104270834000_15.2.e088998.36","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ehf2.12221","article-title":"The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure","volume":"5","author":"Okabe","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2025070104270834000_15.2.e088998.37","first-page":"101517","article-title":"Prognostic impact of outpatient loop diuretic reduction patterns in patients with chronic heart failure","volume":"55","author":"Koike","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2025070104270834000_15.2.e088998.38","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1253\/circj.CJ-11-1196","article-title":"Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: a report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD)","volume":"76","author":"Hamaguchi","year":"2012","journal-title":"Circ J"},{"key":"2025070104270834000_15.2.e088998.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2004.09.006"},{"key":"2025070104270834000_15.2.e088998.40","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijcard.2014.09.156","article-title":"Lowering furosemide dose in stable chronic heart failure patients with reduced ejection fraction is not accompanied by decompensation: a randomized study","volume":"177","author":"Kapelios","year":"2014","journal-title":"Int J Cardiol"},{"key":"2025070104270834000_15.2.e088998.41","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(20)31805-2"},{"key":"2025070104270834000_15.2.e088998.42","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1038\/s41598-023-34028-8","article-title":"Impact of infection-related admission in patients with heart failure: a 10 years national cohort study","volume":"13","author":"Chen","year":"2023","journal-title":"Sci Rep"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:57:22Z","timestamp":1754495842000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-088998"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088998","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}